We're bring back these psychedelic drugs, 'but as a medical treatment against various forms of mental health issues': atai Life Sciences Founder

Christian Angermayer, atai Life Sciences Founder & Chairman, joined Yahoo Finance Live to break down atai's public debut on the Nasdaq and the future of the psychedelic sector.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting